MindMed Inc.
NEO: MMED, OTCQB:MMEDF, DE: BGHM
Company Overview
The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD, is pursuing experiential psychedelic assisted therapy for the treatment of anxiety, and is collaborating on a clinical trial to evaluate LSD for the treatment of cluster cluster headaches.
The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines.
Financial Highlights
$0
Revenue (ttm)
$0
Gross Profit (ttm)
$0.00
Diluted EPS (ttm)
Management Team
Mr. Jamon Alexander Rahn
Co-Founder, CEO & Director
Dr. Miriam Halperin Wernli
Exec. Pres & Director
Dr. Scott M. Freeman
Co-Founder & Clinical Advisor
Mr. Leonard Latchman
Co-founder
Mr. David Dean Guebert
Chief Financial Officer
Ms. Carol Nast
Chief Operating Officer
Mr. Bradford Cross
Chief Technology Officer
Dr. Donald R. Gehlert Ph.D.
Chief Scientific Officer & Member of Scientific Advisory Board
Ms. Madeline Feldman
Director of Operations & Admin.
Mr. Collin Gage
VP of Corp. Devel.
Key Highlights
Market Capitalization
$862,163,575
Shares Outstanding
225,697,271
Shares Short (% of Float)
()
Insider Ownership
0%